Abstract
The lack of serum biomarkers for assessing the prognosis of patients with cerebral glioblastoma multiforme (GBM) prompted the present study in order to evaluate the significance of serum YKL-40 values in patients operated on for glioblastoma. An homogeneous population of 60 patients who underwent surgical removal of GBM underwent a standard treatment (surgery, radiotherapy, chemotherapy in the same schedule) and standard radiological monitoring (same MRI sequences at pre-defined stages). Serum YKL-40 levels (Quidel Corporation, San Diego, CA) were evaluated after dividing patients into two groups on the basis of the extent of resection (total or sub-total) according to the MRI results obtained within 48 h following surgery. YKL-40 serum values, significantly higher in GBM patients than in healthy subjects, were also higher among patients who had undergone subtotal resection than in patients who underwent extensive resection. The effect of YKL-40 on overall survival was analyzed by comparing the change in marker concentration occurring in the first postoperative week with the baseline value. A significant (P = 0.04) hazards ratio of 1.97 was found at multivariate analysis. A significant association with shorter outcome (median survival time, 76 days) was found in patients whose postoperative YKL-40 concentration increases higher than, or equal to, 100%; a 50% increase can still be considered a negative prognostic index. The evaluation of the biochemical marker YKL-40 might provide earlier and additional information to that obtained using traditional factors and be a further aid in establishing the prognosis of GBM patients who have undergone surgery.
Similar content being viewed by others
References
Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9:453–461
Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359:492–507
Tanwar MK, Gilbert MR, Holland EC (2002) Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res 62:4364–4368
Nutt CL, Betensky RA, Brower MA et al (2005) YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas. Clin Cancer Res 11:2258–2264
Nigro JM, Misra A, Zhang L et al (2005) Integrated array comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res 65:1678–1686
Johansen JS, Christensen IJ, Riisbro R, Greenall M, Han C, Price PA, Smith K, Brunner N, Harris AL (2003) High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival. Breast Cancer Res Treat 80:15–21
Johansen JS, Drivsholm L, Price PA, Christensen IJ (2004) High serum YKL-40 level in patients with small cell lung cancer is related to early death. Lung Cancer 46:333–340
Hormigo A, Gu B, Karimi S, Riedel E, Panageas KS, Edgar MA et al (2006) YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res 12:5698–5704
Pelloski CE, Mahajan A, Maor M et al (2005) YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin Cancer Res 11:3326–3334
Shah GD, Kesari S, Xu R et al (2006) Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas. Neuro-oncology 8:38–46
Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216
Rees J (2003) Advances in magnetic resonance imaging of brain tumours. Curr Opin Neurol 16:643–650
Hogdall EVS, Johansen JS, Kjaer SK, Price PA, Blaakjaer J, Hogdall CK (2000) Stability of YKL-40 concentration in blood samples. Scand J Clin Lab Invest 60:247–252
Junker N, Johansen JS, Anderson CB, Kristjansen PEG (2005) Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer. Lung Cancer 48:223–231
Shostak K, Dmitrenko V, Labunskyy V et al (2003) HC gp-39 gene is up-regulated in glioblastomas. Cancer Lett 198:203–210
Johansen JS, Baslund B, Garbarsch C et al (1999) YKL-40 in giant cells and macrophages from patients with giant cell arteritis. Arthr Rheum 42:2624–2630
Park CK, Lee SH, Han JH et al (2009) Recursive partitioning analysis of prognostic factors in WHO grade III glioma patients treated with radiotherapy or radiotherapy plus chemotherapy. BMC Cancer 9:450
Johansen JS, Bojesen SE, Tybjaerg-Hansen A et al (2010) Plasma YKL-40 and total and disease-specific mortality in the general population. Clin Chem 56:1580–1591
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bernardi, D., Padoan, A., Ballin, A. et al. Serum YKL-40 following resection for cerebral glioblastoma. J Neurooncol 107, 299–305 (2012). https://doi.org/10.1007/s11060-011-0762-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-011-0762-7